https://ir.stockpr.com/cytodyn/sec-filings-em...ex99_1.htm
Slide #7
Data and Safety Monitoring Board (DSMB) met Dec 2025 and March 2026
Slide 9
Numeric Increases in PDL1 observed in majority of patients
Slides 12-14
The patient (103-001) with multiple lines prior treatment including Kras mutation was treated with 350mg
8 Weeks ctDna = -97%, Tumor Volume = -21% , CPS (PDL1) increased from 1% to 5%
Slide 16
-Clover - Amendment #6 - Rollover arm for salvage therapy for patients with documented progression (Leronlimab 700mg + ICI)
-City Of Hope HAI
ctDna results from patients on Leron monotherapy
Leron + ICI in patients w/ CRC
Slide 20
Looks like pre-spy and I spy 2.2
Pre Spy MD Anderson = Dose escalation: Safety, PK, ctDna, PDL1
I Spy 2.2 Multi Location = Contribution of Components (+ - ICI )
Up to 120 patients